West Pharmaceutical Services, Inc. (NYSE: WST – Get a rating) – Jefferies Financial Group dropped its second-quarter 2022 earnings estimates for West Pharmaceutical Services in a report released Monday, July 11. Jefferies Financial Group analyst D. Windley now expects the medical device supplier to earn $2.11 per share for the quarter, down from its previous estimate of $2.13. The consensus estimate for West Pharmaceutical Services’ current annual earnings is $9.33 per share. Jefferies Financial Group also released estimates for West Pharmaceutical Services’ third quarter 2022 earnings at $2.27 EPS, fiscal year 2022 earnings at $9.12 EPS and fiscal year 2023 earnings at 10, EPS $24.
Separately, StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a Thursday, April 28 research note.
NYSE:WST shares opened at $296.77 on Wednesday. West Pharmaceutical Services has a 12-month low of $275.89 and a 12-month high of $475.35. The company has a market capitalization of $21.98 billion, a price-to-earnings ratio of 32.97, a growth price-to-earnings ratio of 3.28 and a beta of 1.13. The company has a 50-day moving average price of $302.69 and a 200-day moving average price of $359.60. The company has a current ratio of 2.89, a quick ratio of 2.18 and a debt ratio of 0.09. West Pharmaceutical Services (NYSE: WST- Get a rating) last released its quarterly earnings data on Thursday, April 28. The medical device supplier reported EPS of $2.30 for the quarter, beating the consensus estimate of $2.18 by $0.12. The company had revenue of $720.00 million in the quarter, versus a consensus estimate of $720.92 million. West Pharmaceutical Services achieved a net margin of 23.76% and a return on equity of 30.33%. The company’s quarterly revenue increased by 7.4% compared to the same quarter last year. In the same period a year earlier, the company posted earnings of $2.05 per share.
A number of hedge funds have recently increased or reduced their holdings in WST. Modera Wealth Management LLC bought a new position in shares of West Pharmaceutical Services during the fourth quarter worth approximately $285,000. ARK Investment Management LLC purchased a new position in shares of West Pharmaceutical Services during the first quarter worth approximately $179,000. Robeco Institutional Asset Management BV increased its stake in shares of West Pharmaceutical Services by 10.6% during the fourth quarter. Robeco Institutional Asset Management BV now owns 167,783 shares of the medical device supplier valued at $78,693,000 after buying an additional 16,138 shares in the last quarter. Mirabella Financial Services LLP increased its stake in shares of West Pharmaceutical Services by 70.3% during the fourth quarter. Mirabella Financial Services LLP now owns 21,864 shares of the medical device supplier valued at $10,254,000 after purchasing an additional 9,024 shares last quarter. Finally, Endowment Wealth Management Inc. purchased a new stock position in West Pharmaceutical Services during the fourth quarter valued at approximately $7,305,000. 93.25% of the shares are held by institutional investors.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 3. Investors of record on Wednesday, July 20 will receive a dividend of $0.18. This represents a dividend of $0.72 on an annualized basis and a yield of 0.24%. The ex-dividend date is Tuesday, July 19. West Pharmaceutical Services’ payout ratio is currently 8.00%.
West Pharmaceutical Services Company Profile (Get a rating)
West Pharmaceutical Services, Inc. designs, manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, Middle East, Africa and Asia-Pacific. It operates in two segments, Proprietary Products and Contract Manufactured Products.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in West Pharmaceutical Services right now?
Before you consider West Pharmaceutical Services, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and West Pharmaceutical Services was not on the list.
While West Pharmaceutical Services currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here